Key facts
- This page summarizes Michelle Patricia Pernice's Form 4 filing for InMed Pharmaceuticals Inc. (MTRI).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 12 Nov 2026, 16:30.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Additional SEC filing notes
Footnote F1
This option represents the right to purchase 37,000 shares of the Issuer's common stock and will vest in equal monthly installments through November 9, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.